Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

Blood

Volumn 120, Issue 1, 2012, Pages 173-180

  Carter, Bing Z ^a   Qiu, Yihua ^a   Huang, Xuelin ^a   Diao, Lixia ^a   Zhang, Nianxiang ^a   Coombes, Kevin R ^a   Mak, Duncan H ^a   Konopleva, Marina ^a   Cortes, Jorge ^a   Kantarjian, Hagop M ^a   Mills, Gordon B ^a   Andreeff, Michael ^a   Kornblau, Steven M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD38 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SURVIVIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CD34 SELECTION; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; EVENT FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY;

EID: 84863574448     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-409888     Document Type: Article

References (50)

1. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352(3):254-266. (Pubitemid 40110814)
2. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5): 1532-1542. (Pubitemid 34925124)
3. Konoplev S, Rassidakis GZ, Estey E, et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007;109(6):1152-1156. (Pubitemid 46435395)
4. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999; 23(4):387-388.
5. Carter B, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood. 2001;97(9):2784-2790.
6. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21(37): 5673-5683. (Pubitemid 35333000)
7. Mahboubi K, Li F, Plescia J, et al. Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest. 2001;81(3): 327-334. (Pubitemid 32245065)
8. Papapetropoulos A, Fulton D, Mahboubi K, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem. 2000; 275(13):9102-9105. (Pubitemid 30185122)
9. Yang L, Cao Z, Li F, et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther. 2004;11(15): 1215-1223. (Pubitemid 39136785)
10. You L, He B, Xu Z, et al. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 2004;64(15):5385-5389. (Pubitemid 39006560)
11. Lu R, Bian F, Zhang X, et al. The beta-catenin/ Tcf4/survivin signaling maintains a less differentiated phenotype and high proliferative capacity of human corneal epithelial progenitor cells. Int J Biochem Cell Biol. 2011;43(5):751-759.
12. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell. 2003;14(8): 3325-3341. (Pubitemid 37013130)
13. Gassmann R, Carvalho A, Henzing AJ, et al. Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol. 2004;166(2):179-191. (Pubitemid 38988771)
14. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3(1):46-54. (Pubitemid 37328886)
15. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580-584. (Pubitemid 28563719)
16. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006;18(6):609-615. (Pubitemid 44692469)
17. Carter BZ, Andreeff M. Targeting survivin in leukemia. Oncol Rev. 2008;2:19-28.
18. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia. 2009;23(3): 467-476.
19. Carter BZ, Wang R-Y, Schober WD, Milella M, Chism D, Andreeff M. Targeting survivin expression induces cell proliferation defect and subsequent cell death involving the mitochondrial pathway in myeloid leukemic cell. Cell Cycle. 2003; 2(5):488-493.
20. Balkhi MY, Christopeit M, Chen Y, Geletu M, Behre G. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. Exp Hematol. 2008;36(11):1449-1460.
21. Carter BZ, Mak D, Schober WD, et al. Regulation of survivin expression through bcr-abl/MAPK cascade: targeting survivin overcomes Imatinib resistance and increases Imatinib sensitivity in imatinib responsive CML cells. Blood. 2006;107(4): 1555-1563. (Pubitemid 43242394)
22. Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD. Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia. 2010;24(11):1920-1926.
23. Tamm I, Richter S, Oltersdorf D, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2004;10(11):3737-3744. (Pubitemid 38697607)
24. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22(9):1682-1688. (Pubitemid 41079807)
25. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96(5):1921-1925. (Pubitemid 30661078)
26. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000; 111(1):196-203.
27. Carter BZ, Kornblau SM, Tsao T, et al. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood. 2003;102(12):4179-4186. (Pubitemid 37487005)
28. Sugahara K, Uemura A, Harasawa H, et al. Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int J Hematol. 2004;80(1):52-58. (Pubitemid 38937875)
29. Kornblau SM, Tibes R, Qiu YH, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113(1):154-164.
30. Tibes R, Qiu YH, Lu Y, et al. Reverse phase protein array (RPPA): validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells (HSC). Mol Cancer Ther. 2006;5(10):2512-2521. (Pubitemid 44650915)
31. Carter B, Qiu YH, Zhang N, et al. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011;117(3): 780-787.
32. Grimwade D. Impact of cytogenetics on clinical outcome in AML. In: Karp JE, ed. Acute Myeloid Leukemia. Totowa, NJ: Humana Press; 2007: 177-192.
33. Hunyady B, Krempels K, Harta G, Mezey E. Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem. 1996;44(12):1353-1362.
34. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics. 2007;23(15):1986-1994. (Pubitemid 47299840)
35. Neeley ES, Kornblau SM, Coombes KR, Baggerly KA. Variable slope normalization of reverse phase protein arrays. Bioinformatics. 2009; 25(11):1384-1389.
36. R: A language and environment for statistical computing. Vienna, Austria: R Development Core Team; 2009.
37. Fukuda S, Conway EM, Pelus LM. Survivin regulates proliferation of normal hematopoietic stem and progenitor cells in vivo. Blood (ASH Annual Meeting Abstracts). 2006;108(11):258b. Abstract 859.
38. Benito J, Shi Y, Szymanska B, et al. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011;6(8):e23108.
39. Sprenger T, Rodel F, Beissbarth T, et al. Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res. 2011;17(6):1623-1631.
40. Hope KJ, Cellot S, Ting SB, et al. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Cell Stem Cell. 2010;7(1):101-113.
41. Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. Blood. 2011;118(10):2857-2867.
42. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell. 2010;17(1):53-64.
43. Fukuda S, Singh P, Moh A, et al. Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood. 2009; 114(2):394-403.
44. Talbot DC, Ranson M, Davies J, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-inhuman dose study. Clin Cancer Res. 2010; 16(24):6150-6158.
45. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67(17):8014-8021. (Pubitemid 47395135)
46. Giaccone G, Zatloukal P, Roubec J, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27(27):4481-4486.
47. Cheson BD, Bartlett NL, Vose JM, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma [published online ahead of print October 17, 2011]. Cancer. doi:10.1002/cncr. 26510.
48. Tolcher AW, Quinn DI, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxanepretreated prostate cancer. Ann Oncol. 2012; 23(4):968-973.
49. Lewis KD, Samlowski W, Ward J, et al. A multicenter phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011;29(1):161-166.
50. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/ beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650-1653.